Trials / Recruiting
RecruitingNCT06565247
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Region Västerbotten · Other Government
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.
Detailed description
Open, non-randomized, prospective multi-center trial, with consecutive recruiting, between Skåne University hospital and Umeå University Hospital. High-risk prostate cancer patients referred for radical prostatectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]PSMA-PET | Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection. |
| DEVICE | MRI sequences optimized for prostate cancer examinations | T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital |
Timeline
- Start date
- 2024-10-14
- Primary completion
- 2026-12-01
- Completion
- 2031-12-01
- First posted
- 2024-08-21
- Last updated
- 2025-03-04
Locations
2 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06565247. Inclusion in this directory is not an endorsement.